Microvascular Therapeutics

Microvascular Therapeutics (MVT) has developed breakthrough microbubble and nanobubble technologies that unlock the potential of ultrasound in diagnosis and therapy. MVT is developing CardiSon, a next-generation microbubble contrast agent that will be the best performing contrast agent on the market in terms of ease-of-use, side effects, and contrast enhancement which is in late-stage clinical development via an abbreviated pathway. This microbubble is a platform for nanobubbles that offer therapeutics uses for a broad scope of diseases, including oncology, blood clots, and Alzheimer's disease.